ArticleMedicine2026
Pulmonary sarcomatoid carcinoma in the anterior mediastinum mimicking thymic carcinoma with rapid widespread metastases: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationalePulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small-cell lung cancer. Marked histologic heterogeneity, nonspecific imaging findings, and limited representation in small biopsy specimens can cause diagnostic error, particularly when a pulmonary lesion abuts the anterior mediastinum and mimics a thymic tumor. PATIENT CONCERNS: A 67-year-old woman presented to a local hospital in Hangzhou with chest pain, low-grade fever, and intermittent hemoptysis. Imaging showed a mass abutting the anterior mediastinum and adjacent lung parenchyma. Core needle biopsy showed predominantly spindle cells with few atypical epithelioid cells in a lymphocyte-rich background and was interpreted as thymic carcinoma. She was subsequently transferred to Zhejiang Hospital for further evaluation. DIAGNOSES: Continued progression during docetaxel-cisplatin chemotherapy and persistent diagnostic uncertainty prompted video-assisted thoracoscopic wedge resection. The resected tumor showed markedly atypical spindle cells, pan-cytokeratin and vimentin positivity, thyroid transcription factor 1 negativity, and an elevated Ki-67 proliferation index. Programmed death-ligand 1 testing showed a tumor proportion score of approximately 10% and a combined positive score of approximately 20%. KRAS p.A146T and NRAS p.Q61K mutations were identified. Integrated histomorphologic, immunohistochemical, and molecular assessment established the diagnosis of PSC.
interventionsThe patient initially received docetaxel plus cisplatin. Because of continued disease progression, declining performance status, and myelosuppression and gastrointestinal adverse effects during platinum-based chemotherapy, cisplatin was discontinued. The patient subsequently received dose-reduced docetaxel plus pembrolizumab as an individualized treatment strategy intended to balance continued systemic therapy with tolerability. OUTCOMES: The disease progressed rapidly with metastases to the lungs, bone, soft tissue, liver, pancreas, and adrenal gland. The patient died of respiratory failure secondary to widespread tumor dissemination. LESSONS: PSC should be considered when an apparent anterior mediastinal mass shows spindle cell morphology or discordant clinicoradiologic and pathologic findings. Adequate representative tissue and integrated radiologic, morphologic, immunohistochemical, and molecular assessment are essential. Rapid progression despite docetaxel plus pembrolizumab indicates that programmed death-ligand 1 positivity alone may not reliably predict immunotherapy benefit, while the clinical significance of rare KRAS/NRAS co-mutations remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.